Members of International Myeloma Foundation's Nurse Leadership Board
Author Key Textbook for Nurses
Book Updates the First Comprehensive Review by and For Nurses (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 22, 2015 Category: Hematology Source Type: news
Calling All Researchers: Submit Your Applications for 2016 IMF Grants
The IMF awards Brian D. Novis Junior and Senior Research Grants each year to "provide much-needed funding support for research projects being conducted by the best and the brightest in our field," according to IMF President Susie Novis. Funding grants since 1994 to honor IMF Co-Founder Brian D. Novis, the IMF has awarded more than 140 grants in 13 countries, which have opened the doors to new ideas and major advancements in treatments. Applications for 2016 grants are due by August 3rd. To submit an application, click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 20, 2015 Category: Hematology Source Type: news
New Drug Application Filed with FDA for Oral Proteasome Inhibitor
Takeda has filed for FDA approval of ixazomib, which could become the first oral proteasome inhibitor for treating multiple myeloma. The New Drug Application (NDA) for ixazomib is based on the results of the phase III TOURMALINE-MM1 trial, which compared ixazomib to placebo—both given in 772 patients with relapsed or refractory myeloma. “If approved, ixazomib, with the convenience of once-a-week oral administration as well as promising efficacy, should provide a very meaningful advance for our patients,” said Dr. Paul Richardson, Clinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myelom...
Source: International Myeloma Foundation - July 17, 2015 Category: Hematology Source Type: news
Expanded Access Program Opens for Daratumumab
Janssen Biotech, Inc. has announced the opening of a daratumumab expanded access program (EAP) at up to 40 medical centers for eligible US myeloma patients who have received at least 3 prior lines of therapy (including a proteasome inhibitor and an immunomodulatory agent) or are double refractory to a proteasome inhibitor and an immunomodulatory agent. Daratumumab is currently an investigational human anti-CD38 monoclonal antibody treatment for multiple myeloma. To learn more about the EAP for daratumumab, contact the IMF InfoLine at (800) 452-2873 or email infoline@myeloma.org. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 17, 2015 Category: Hematology Source Type: news
Is There a Tie Between Leisure Time Spent Sitting and Cancer Risks?
In his blog this week, IMF Chairman Dr. Brian Durie examines a new study in the July 2015 issue of “Cancer Epidemiology, Biomarkers & Prevention” suggesting that women who spend more leisure time sitting may be at a higher risk for multiple myeloma, breast and ovarian cancer. The higher risk was present even after taking into account BMI, physical activity, and other factors. The study found no association between sitting time and cancer risk in men. Click HERE to read his blog. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 16, 2015 Category: Hematology Source Type: news
Clinical Trial Opens for New Generation Proteasome Inhibitor
Dr. Ola Landgren announced the opening of a new Phase I/II clinical trial at Memorial Sloan-Kettering Cancer Center for patients with relapsed and/or refractory myeloma. The trial will test a new proteasome inhibitor called VLX1570, which is given intravenously. VLX1570 was developed by researchers at Sweden's Karolinska Institute. Memorial Sloan-Kettering has some funds available to help patients who demonstrate financial need with transportation and hotel costs. Click HERE to see the full trial listing. Please call the IMF InfoLine at (800) 452-2873 with any further questions. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 11, 2015 Category: Hematology Source Type: news
What Is the Value of Treatment for Individual Cancer Patients?
Having myeloma is undeniably expensive. But will new systems of evaluating the cost and efficacy of treatment end up harming myeloma patients by mandating suboptimal care and eliminating access to needed drugs? In his blog this week, IMF Chairman Brian Durie examines these questions. “Individual patient value must be considered,” he writes. “But how do we do that?” Click HERE to read Dr. Durie's blog. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 10, 2015 Category: Hematology Source Type: news
Get to Know Your Medical Records
Myeloma patients need to have access to their medical records. But gathering years of data from dozens of different providers can be a challenge. At this summer's annual Support Group Leader Summit, the IMF will present an educational session outlining which medical records are most important to have instantly available and how to get them—knowledge that leaders can pass along to their support group members. Another source of guidance was published Monday in a Wall Street Journal article titled “How to Take Charge of Your Medical Records.” And, in time for Independence Day, a campaign called “Get My Health Data,”...
Source: International Myeloma Foundation - July 6, 2015 Category: Hematology Source Type: news
Los Angeles IMF Patient & Family Seminar Announced
The IMF will host a two-day Patient & Family Seminar August 21-22 at the Sheraton Universal Hotel in Los Angeles, California. What do you get at an IMF Patient & Family Seminar? Attendees will receive the latest information on myeloma, access to many of the top myeloma experts, and a chance to share the company and support of other myeloma patients and family members. For more information, or to register, please click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 5, 2015 Category: Hematology Source Type: news
Los Angeles IMF Patient & Family Seminar Announced
The IMF will host a two-day Patient & Family Seminar August 21-22 at the Sheraton Universal Hotel in Los Angeles, California. What do you get at an IMF Patient & Family Seminar? Attendees will receive the latest information on myeloma, access to many of the top myeloma experts, and a chance to share the company and support of other myeloma patients and family members. For more information, or to register, please click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 5, 2015 Category: Hematology Source Type: news
Farydak Receives Positive Recommendation from European Medicines Agency Committee
On June 26, the Committee for Medicinal Products for Human Use (CHMP), an advisory committee of the European Medicines Agency (EMA), released a positive opinion regarding European approval of Farydak® (panobinostat) for the treatment of myeloma in certain cases. While this doesn't mean Farydak has been approved, it's an important first step in the EMA's process. CHMP's statement in particular supports the use of Farydak in combination with Velcade® and dexamethasone for myeloma patients who have relapsed and have already tried at least two prior treatment regimens. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - July 3, 2015 Category: Hematology Source Type: news
Open Call to Nurses to Attend 15th Annual International Myeloma Workshop
The 15th International Myeloma Workshop will be held in Rome, Italy, September 23-26. During this important semi-annual event, a full-day nursing symposium will also take place on Wednesday, September 23rd. Nurses are invited and highly encouraged to attend. The symposium will include a keynote presentation by Joseph Tariman, Assistant Professor, School of Nursing at De Paul University, titled, “Integrating Myeloma Genomics into Nursing Practice: Patient Education and Shared Decision Making.” (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - June 27, 2015 Category: Hematology Source Type: news
The Untenable Cost of Cancer Drugs
The Supreme Court's re-affirmation of Obamacare, aka the Affordable Care Act, is certainly good news, but the rising cost of cancer drugs threatens to bring down our medical insurance infrastructure á even as it places a morally questionable value on human life. “Healthcare is not a luxury, it is what is provided to citizens in a civilized society,” writes IMF Chairman Dr. Brian Durie. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - June 26, 2015 Category: Hematology Source Type: news
Global Myeloma Action Network Tackles Patient Education and Access to Treatment
The IMF’s Global Myeloma Action Network (GMAN) recently gathered during the International Myeloma Working Group (IMWG) Summit in Vienna, Austria. Representatives from myeloma patient groups in 23 countries met to discuss important myeloma issues, which as IMF Global Advocacy Executive Ray Wezik pointed out, also included “many successes.” Patient advocates around the globe are seeking more educational and financial resources, as well as access to more treatment options. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - June 25, 2015 Category: Hematology Source Type: news
Watch Replay of ONS Presentation: Case Studies in Myeloma
The IMF sponsored a presentation of several myeloma case studies at the recent 41st Annual Congress of the Oncology Nursing Society (ONS) in Orlando, FL. The IMF Nurse Leadership Board's Joseph D. Tariman, Ph.D., Beth Faiman, Ph.D.,Teresa Miceli, RN, and Sandra Kurtin, RN, MS, presented “Case Studies in Myeloma: Nursing Implications of Evolving Treatment Paradigms.” To watch the video presentations and see the complete set of slides, click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - June 20, 2015 Category: Hematology Source Type: news
